title: Can oral 1,25(OH)2D3 pulse therapy reduce parathyroid hyperplasia?
authors.forename: T
authors.initials: T
authors.lastname: Hyodo
authors.forename: K
authors.initials: K
authors.lastname: Ono
authors.forename: T
authors.initials: T
authors.lastname: Koumi
authors.forename: M
authors.initials: M
authors.lastname: Ueda
authors.forename: I
authors.initials: I
authors.lastname: Miyagawa
authors.forename: K
authors.initials: K
authors.lastname: Kodani
authors.forename: S
authors.initials: S
authors.lastname: Doi
authors.forename: M
authors.initials: M
authors.lastname: Ishibashi
authors.forename: T
authors.initials: T
authors.lastname: Morita
mesh_terms: D000284:Administration, Oral; D002117:Calcitriol / Q000008:administration & dosage*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D006965:Hyperplasia; D010280:Parathyroid Glands / Q000187:drug effects* / Q000473:pathology; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D002117:Calcitriol